利拉鲁肽、西他列汀和吡格列酮治疗NAFLD合并2型糖尿病患者疗效初步比较研究

doi:10.3969/j.issn.1672-5069.2017.05.026

Abstract

Pang Xiaoning，Liu Yanjun.. A comparative study of liraglutide,sitagliptin and pioglitazone in the treatment of patients with nonalcoholic fatty liver diseases and type 2 diabetes mellitus[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 604-605.

References

[1] 叶启宝，何媛媛，吕齐欢，等. 利拉鲁肽治疗2型糖尿病合并非酒精性脂肪肝患者的临床观察. 医学研究杂志，2015，44（7）:152-154.
[2] 杨璐，宋美情，张秋玲，等. 吡格列酮、二甲双胍对2型糖尿病合并非酒精性脂肪肝患者血清视黄醇结合蛋白4、脂联素水平的影响比较. 中国医学科学院学报，2014，36（3）:309-312.
[3] 牟伦盼，蒋建家，苏劲波，等. 利拉鲁肽与西格列汀对胰岛素控制欠佳的肥胖伴2型糖尿病患者的疗效和安全性比较. 中国糖尿病杂志，2016，8（1）:35-39.
[4] 闫泽强，郭燕，韩晓颖. 吡格列酮联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的临床效果评估. 西部医学，2015，27（7）:1057-1059.
[5] 谭娅琴，王德桂，郭中秋，等. 吡格列酮对非乙醇性脂肪肝大鼠肝脏脂质沉积的影响. 新乡医学院学报，2014，31（4）:256-259.
[6] Kittichai P，Kleiner DE，Niemeier HM，et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology，2010，51（1）:121-129.
[7] 呙劲松，陈艳. 吡格列酮对糖耐量异常合并非酒精性脂肪肝患者血浆瘦素水平及胰岛素抵抗的影响. 中南医学科学杂志，2014，14（4）:379-381.
[8] Ohki T，Isogawa A，Iwamoto M，et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Sci World J，2012，2012（3）:245-251.
[9] Kim SS，Kim IJ，Lee KJ，et al. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes:A multicenter randomized double-blind study. J Diabetes，2016，27（1）:1-4.
[10] Hoffmanová I， krha P，edo A，et al. Dynamic change of focal fatty sparing in non-alcoholic fatty liver disease after treatment with sitagliptin. Ultrasound Int Open，2016，2（3）:E98-107.
[11] Gupta NA，Mells J，Dunham RM，et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro，by modulating elements of the insulin signaling pathway. Hepatology，2010，51（5）:1584-1592.
[12] 李芳芳，张黎军，田海军,等. 胰岛素抵抗大鼠血清淀粉样蛋白A、视黄醛结合蛋白4、肝脏抵抗素样分子α的表达及吡格列酮的干预作用. 中国糖尿病杂志，2015,7（3）:161-165.
[13] 王景玲，叶文雄，丘明宇，等. NAFLD患者动脉僵硬度的变化及其影响因素分析.实用肝脏病杂志，2016，19（3）:347-349.

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[5]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[6]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[7]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[8]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[9]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[10]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[14]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.
[15]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.

A comparative study of liraglutide,sitagliptin and pioglitazone in the treatment of patients with nonalcoholic fatty liver diseases and type 2 diabetes mellitus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments